| Literature DB >> 31924724 |
Susanne Lütje1, Georg Feldmann2, Markus Essler3, Peter Brossart2, Ralph A Bundschuh3.
Abstract
Immune checkpoint blockade represents a promising approach in oncology, showing antitumor activities in various cancers. However, although being generally far better tolerated than classic cytotoxic chemotherapy, this treatment, too, may be accompanied by considerable side effects and not all patients benefit equally. Therefore, careful patient selection and monitoring of the treatment response is mandatory. At present, checkpoint-specific molecular imaging is being increasingly investigated as a tool for patient selection and response evaluation. Here, an overview of the current developments in immune checkpoint imaging is provided.Entities:
Keywords: PET/CT; checkpoint blockade; molecular imaging; oncology
Mesh:
Year: 2020 PMID: 31924724 PMCID: PMC7413235 DOI: 10.2967/jnumed.119.237891
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057